609 related articles for article (PubMed ID: 11406724)
21. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.
Saucedo JF; Lui HK; Garza L; Guerra GJ; Jacoski MV; Jennings LK
J Thromb Thrombolysis; 2004 Oct; 18(2):67-74. PubMed ID: 15789173
[TBL] [Abstract][Full Text] [Related]
22. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Jennings LK; Jacoski MV; White MM
J Interv Cardiol; 2002 Feb; 15(1):45-60. PubMed ID: 12053684
[TBL] [Abstract][Full Text] [Related]
23. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M
J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442
[TBL] [Abstract][Full Text] [Related]
24. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Jennings LK
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
[TBL] [Abstract][Full Text] [Related]
25. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
[TBL] [Abstract][Full Text] [Related]
26. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
[TBL] [Abstract][Full Text] [Related]
27. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
28. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
[TBL] [Abstract][Full Text] [Related]
29. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Dunn A
Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
[No Abstract] [Full Text] [Related]
30. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Weber AA; Schrör K
Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
Cheng JW
Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
33. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
34. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
Bertram U; Moser M; Peter K; Kuecherer HF; Bekeredjian R; Straub A; Nordt TK; Bode C; Ruef J
J Thromb Thrombolysis; 2002 Dec; 14(3):197-203. PubMed ID: 12913399
[TBL] [Abstract][Full Text] [Related]
35. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B
Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042
[TBL] [Abstract][Full Text] [Related]
36. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
37. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M; Bertram U; Peter K; Bode C; Ruef J
J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Tardiff BE; Jennings LK; Harrington RA; Gretler D; Potthoff RF; Vorchheimer DA; Eisenberg PR; Lincoff AM; Labinaz M; Joseph DM; McDougal MF; Kleiman NS;
Circulation; 2001 Jul; 104(4):399-405. PubMed ID: 11468200
[TBL] [Abstract][Full Text] [Related]
39. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
40. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Saucedo JF; Garza L; Wolford DC; Cook SL; Ramanathan KB; Matin Z; McGrew FA; Jacoski MV; Jennings LK;
Am J Cardiol; 2004 May; 93(10):1279-82. PubMed ID: 15135704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
